Esperion Therapeutics (NASDAQ:ESPR) Earns “Market Outperform” Rating from JMP Securities

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “market outperform” rating restated by equities researchers at JMP Securities in a report released on Tuesday,Benzinga reports. They presently have a $4.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $7.00. JMP Securities’ price objective points to a potential upside of 112.77% from the stock’s previous close.

Several other brokerages also recently issued reports on ESPR. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a report on Tuesday. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 target price on shares of Esperion Therapeutics in a research note on Friday, December 13th. The Goldman Sachs Group initiated coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price target for the company. Cantor Fitzgerald began coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price objective on the stock. Finally, StockNews.com cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Esperion Therapeutics presently has an average rating of “Hold” and an average target price of $6.75.

Esperion Therapeutics Stock Performance

Shares of NASDAQ:ESPR opened at $1.88 on Tuesday. The company’s fifty day moving average is $2.28 and its two-hundred day moving average is $2.12. Esperion Therapeutics has a 1-year low of $1.58 and a 1-year high of $3.94. The stock has a market capitalization of $370.44 million, a price-to-earnings ratio of -2.94 and a beta of 1.01.

Institutional Trading of Esperion Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rangeley Capital LLC bought a new position in shares of Esperion Therapeutics in the fourth quarter valued at approximately $235,000. Headlands Technologies LLC boosted its stake in Esperion Therapeutics by 55.0% during the 4th quarter. Headlands Technologies LLC now owns 255,066 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 90,522 shares in the last quarter. Summit Financial LLC increased its position in shares of Esperion Therapeutics by 18.2% during the 4th quarter. Summit Financial LLC now owns 46,528 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 7,150 shares during the period. JPMorgan Chase & Co. increased its position in shares of Esperion Therapeutics by 18.6% during the 4th quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company’s stock valued at $5,399,000 after purchasing an additional 385,099 shares during the period. Finally, Virtu Financial LLC bought a new stake in shares of Esperion Therapeutics in the 4th quarter worth $291,000. 47.39% of the stock is currently owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.